Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057129 | 0.87 | KMT2A (0.69) | KMT2ASMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL11044058 | 0.86 | HPGD (0.56) | HPGDKMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5051428 | 0.86 | THRB (0.60) | KMT2AMEN1GSK3BMAPK1NR1H4 | |
| SCHEMBL7913254 | 0.85 | HPGD (0.55) | HPGDKMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8085066 | 0.84 | THRB (0.66) | KMT2AGSK3BNR1H4 | |
| SCHEMBL9559962 | 0.83 | HPGD (0.54) | HPGDKMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2379429 | 0.83 | RAB9A (0.55) | HPGDKMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5312197 | 0.83 | THRB (0.68) | KMT2ANR1H4 | |
| SCHEMBL29381265 | 0.83 | CES2 (0.65) | KMT2ASMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL202150 | 0.83 | CES2 (0.65) | KMT2ASMN1; SMN2ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1013444-B | PROCESS FOR THE PREPARATION OF A NOVEL CLASS OF HYPOGLYCEMIC AGENTS | LILLY CO ELI (US) | 1991-08-07 | — | — | CN | claimed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1699759-B1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0182533-B1 | 3-(2-ARYL-2-OXOETHYL)-IMIDAZOLIUM SALTS AS HYPOGLYCEMIC AGENTS | ELI LILLY AND COMPANY (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4683312-A | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| US-4609670-A | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1986-09-02 | — | — | US | disclosed |
| EP-0182533-A2 | 3-(2-Aryl-2-oxoethyl)-imidazolium salts as hypoglycemic agents | ELI LILLY AND COMPANY (US) | 1986-05-28 | — | — | EP | disclosed |
| EP-0016277-B1 | 2-CARBONYL-3-HYDROXY-ALKENONITRILES, THEIR USE AS ANTI-ARTHRITIC AGENTS AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| WO-1980000964-A1 | ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES | AMERICAN CYANAMID CO (US) | 1980-05-15 | — | — | WO | disclosed |
| US-4173650-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-11-06 | — | — | US | disclosed |
| US-4033978-A | Thiacycl[2.2.2]azine carboxylic acids | SYNTEX (U.S.A.) INC. (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | HPGD 1463/4885KMT2A 127/4885SMN1; SMN2 1863/4885 |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | HPGD 323/4885KMT2A 3616/4885SMN1; SMN2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.